Related references
Note: Only part of the references are listed.Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer
Alessandro Ottaiano et al.
CELL DEATH & DISEASE (2020)
Study of Ras Mutations' Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
Alessandro Ottaiano et al.
CANCERS (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer
Alessandro Ottaiano et al.
CANCERS (2020)
Targeting the RAS-dependent chemoresistance: The Warburg connection
Roberto Serna-Blasco et al.
SEMINARS IN CANCER BIOLOGY (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives
Anna Nappi et al.
CURRENT CANCER DRUG TARGETS (2018)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes
William J. Hadden et al.
HPB (2016)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Share Paper
